IQVIA UK and Ireland ’s Post

The speed of innovation and steepness of cost trend in the oncology drug space is at an all-time high. Using a collaborative model like ours to increase the use of higher-value (which, by the way, does not always mean lowest cost) treatment regimens is one of many important tools we can deploy to address this need.

With the prevalence of cancer and the rapid increase in cancer treatment costs, a value-based approach is critical to ensure the best possible cancer care without unnecessary spending. Learn how eviCore’s Oncology Value-based Pathways program is helping: https://bit.ly/4aHbOj5

April is Testicular Cancer Awareness Month. This month our study on high-risk testicular tumors has been accepted for presentation at the Annual Meeting of American Society of Clinical Oncology (ASCO) - Chicago. More details on study results in June! #testicularcancerawareness #cancerawareness #ASCO

About one-third of patients newly diagnosed with cancer reported having a major adverse financial event (AFE) before diagnosis, and those with previous AFEs are more likely to be diagnosed with later-stage cancer, according to a study published online Feb. 6 in the Journal of Clinical Oncology. https://buff.ly/3Ve5nOS #AdverseFinancialEvent #CancerPatients #SeriousIllness

This episode of Oncology Today features a conversation between Dr Neil Love and Dr Komal Jhaveri about the efficacy, selection and sequencing of available and investigational oral SERDs for the treatment of ER-positive metastatic breast cancer. https://bit.ly/4caLDlE

The evolving world of cancer treatment: Specialization in oncology. Really enjoyed this interview with Professor Tim Price about oncology. In this snippet, he outlines the development of specialisation in oncology. #medicalpodcast, #medicaleducation, #oncology

Are you willing to publish a short article in Cancerworld magazine? - European School of Oncology SPCC (Sharing Progress in Cancer Care) #AIInOncology #Cancer #Cancerworld #ESCO #OncoDaily #Oncology

Dr. Mims, a renowned medical oncologist and associate professor at The Ohio State University Comprehensive Cancer Center, explores the potential of emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, in heavily pretreated patients with FLT3-mutated relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. The phase 1/2a TakeAim Leukemia trial (NCT04278768) is currently assessing emavusertib's efficacy in these challenging cases. https://lnkd.in/dpdNT5bH

In an interview with Targeted Oncology, Premal Thaker, MD, discussed the ACCC Ovarian Quality of Care Project aiming to bridge the gap to improve ovarian cancer care for patients in the US. https://lnkd.in/ezB3GXDE